Insider Selling: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Insider Sells 2,241 Shares of Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) insider Ellen Chiniara sold 2,241 shares of the firm’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $68,238.45. Following the completion of the sale, the insider now directly owns 80,085 shares of the company’s stock, valued at $2,438,588.25. This represents a 2.72 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Ellen Chiniara also recently made the following trade(s):

• On Monday, January 6th, Ellen Chiniara sold 3,129 shares of Kymera Therapeutics stock. The stock was sold at an average price of $41.75, for a total value of $130,635.75.

Kymera Therapeutics Trading Up 3.3 %

Shares of KYMR opened at $31.70 on Thursday. Kymera Therapeutics, Inc. has a 12-month low of $29.07 and a 12-month high of $53.27. The company has a market cap of $2.06 billion, a PE ratio of -13.55 and a beta of 2.22. The stock has a 50-day moving average price of $38.42 and a 200-day moving average price of $43.48.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.12). The company had revenue of $7.39 million during the quarter, compared to analysts’ expectations of $14.81 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. As a group, analysts predict that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on KYMR. Wells Fargo & Company upgraded Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $38.00 to $57.00 in a research note on Monday, December 2nd. Stephens reissued an “overweight” rating and issued a $60.00 price target on shares of Kymera Therapeutics in a research report on Tuesday, January 21st. HC Wainwright upped their price target on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, February 28th. BMO Capital Markets assumed coverage on shares of Kymera Therapeutics in a research note on Friday, December 6th. They issued a “market perform” rating and a $55.00 price objective for the company. Finally, Leerink Partners restated an “outperform” rating and set a $60.00 target price on shares of Kymera Therapeutics in a research report on Friday, December 27th. Three research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $56.69.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in KYMR. Blue Trust Inc. lifted its stake in Kymera Therapeutics by 74.8% during the fourth quarter. Blue Trust Inc. now owns 631 shares of the company’s stock worth $25,000 after purchasing an additional 270 shares during the last quarter. State of Wyoming bought a new stake in Kymera Therapeutics in the 4th quarter worth approximately $45,000. GF Fund Management CO. LTD. bought a new stake in Kymera Therapeutics in the 4th quarter worth approximately $55,000. Quarry LP purchased a new stake in Kymera Therapeutics in the third quarter worth approximately $95,000. Finally, KBC Group NV grew its position in Kymera Therapeutics by 53.8% during the fourth quarter. KBC Group NV now owns 2,151 shares of the company’s stock valued at $87,000 after acquiring an additional 752 shares during the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.